

# The practicalities of eosinophilic oesophagitis management: A closer look at emerging biologic treatment options



## Disclaimer

- *Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions*
- *The presenting faculty have been advised by USF Health and touchIME to ensure that they disclose any such references made to unlabelled or unapproved use*
- *No endorsement by USF Health and touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in USF Health or touchIME activities*
- *USF Health and touchIME accepts no responsibility for errors or omissions*

## Expert panel



**Dr Nirmala Gonsalves**

Northwestern University Feinberg School  
of Medicine, Chicago, USA



**Dr Sharon Hall**

Imperial College Healthcare NHS Trust,  
London, UK



**Dr Salvatore Oliva**

Sapienza University of Rome,  
Rome, Italy



# Agenda

**EoE in children and adults: What are the similarities and differences?**

**Caring for children with EoE: How can we manage the transition to adult services?**

**Treating children and adults with EoE: What do the latest data show?**




# EoE in children and adults: What are the similarities and differences?

**Dr Nirmala Gonsalves**

Northwestern University Feinberg  
School of Medicine, Chicago, USA




# Underlying mechanisms of EoE development<sup>1,2</sup>



EoE, eosinophilic oesophagitis.

1. Muir A, Falk GW. *JAMA*. 2021;326:1310–8; 2. Racca F, et al. *Front Physiol*. 2022;12:815842.


# EoE pathophysiology overview<sup>1-5</sup>



EoE, eosinophilic esophagitis; IL, interleukin; IL-5R $\alpha$ , IL-5 receptor  $\alpha$ ; ILC2, type 2 innate lymphoid cells; Siglec-8, sialic acid-binding Ig-like lectin 8; SP1R, sphingosine-1-phosphate receptor; TGF- $\beta$ , transforming growth factor- $\beta$ ; Th2, T-helper cell type 2; TNF- $\alpha$ , tumour necrosis factor- $\alpha$ ; TSLP, thymic stromal lymphopoietin.

1. Muir A, Falk GW. *JAMA*. 2021;326:1310-8; 2. Racca F, et al. *Front Physiol*. 2022;12:815842; 3. Furuta GT, Katzka DA. *N Engl J Med*. 2015;373:1640-8; 4. Hill DA, Spergel JM. *J Allergy Clin Immunol*. 2018;142:1757-8; 5. Lam AY, et al. *Curr Opin Pharmacol*. 2022;63:102183.

# EoE as a continuum from inflammation to fibrosis







# Caring for children with EoE: How can we manage the transition to adult services?

**Dr Nirmala Gonsalves**

Northwestern University Feinberg  
School of Medicine, Chicago, USA



# Many patients with EoE are lost to follow-up




Retrospective chart review of patients with EoE at a tertiary care medical centre




N=177 patients with EoE:

- n=41 children (<21 years)
- n=136 adults (>21 years)

Proportion of patients with EoE lost to follow-up (not seen for >1 year)



Median length of follow-up (months)



Findings underscore the importance of effective transition of care, and ensuring patients engage with ongoing management and follow-up

# Transition of care: Patient and provider responsibilities



## Patient responsibilities

- Know disease name and medications<sup>1</sup>
- Understand treatments, procedures and risk of non-adherence or loss to follow-up<sup>1</sup>
- Participate in decision making<sup>1</sup>
- Assume responsibility for own care, e.g. appointments, prescriptions<sup>1</sup>

## Paediatric provider responsibilities

- Introduce transfer of care<sup>1,2</sup>
- Develop individualized care transition plan<sup>1,3</sup>
- Address misunderstandings<sup>2</sup>
- Identify psychological, social or economic issues<sup>2</sup>
- Ongoing assessment of transition readiness; \* identify and address areas for improvement<sup>1,3</sup>
- Promote self-management skills<sup>2</sup>
- Discuss individualized care plan and simplified treatment regimen<sup>2</sup>
- Continue or establish care with adult sub-specialists, e.g. allergists and dietitians<sup>1</sup>
- Discuss implications of EoE for education and work<sup>2</sup>

## Adult provider responsibilities

- Joint review of patient case<sup>1,3</sup>
- Joint visits with paediatric and adult gastroenterologists, allergists and dietitians<sup>1,3</sup>
- Transfer to adult clinic<sup>1,3</sup>
- Assume and continue care<sup>3</sup>

\*Includes understanding medical condition, knowledge of medications, obtaining refills, scheduling appointments, maintaining health records and functioning independently in the health care setting.<sup>3</sup>

EoE, eosinophilic oesophagitis.

1. Hiremath G, et al. *Trans Sci Rare Dis.* 2022;6:13–23; 2. Roberts G, et al. *Allergy.* 2020;75:2734–52; 3. Dellon ES, et al. *Dis Esophagus.* 2013;26:7–13.

# Treating children and adults with EoE: What do the latest data show?


## **Dr Nirmala Gonsalves**

Northwestern University Feinberg  
School of Medicine, Chicago, USA



# Treatment of patients with EoE: Clinical decision support tool<sup>1-5</sup>

★ EGD with biopsy to assess treatment response



\*Dupilumab is approved by the FDA to treat patients with EoE aged 12 years and older, weighing at least 40 kg. Dupilumab is currently under EMA/CHMP review. CHMP, Committee for medicinal products for human use; EGD, oesophagogastroduodenoscopy; EMA, European Medicines Agency; EoE, eosinophilic oesophagitis. 1. Hirano I, et al. *Gastroenterology*. 2020;158:1776–86; 2. Rank MA, et al. *Gastroenterology*. 2020;158:1789–810; 3. Rank MA, et al. *Ann Allergy Asthma Immunol*. 2020;124:424–40; 4. Hirano I, et al. *Ann Allergy Asthma Immunol*. 2020;124:416–23; 5. FDA. Dupilumab prescribing information 2022. Available at: [www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/761055s040lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761055s040lbl.pdf) (accessed 7 June 2022).

# Selected agents in development targeting EoE pathophysiology

## Study details

Estimated completion

**Cendakimab (IL-13)<sup>1,2</sup>**  
 NCT05175352  
 Age 18 to 75 years  
 March 2024

**Etrasimod (SP1R)<sup>1,2</sup>**  
 NCT04682639 (VOYAGE)  
 Age 18 to 65 years~  
 May 2023

**Cendakimab (IL-13)<sup>1,2</sup>**  
 NCT04753697; NCT04991935  
 Age 12 to 75 years  
 July 2024; August 2026

**Dupilumab (IL-4R $\alpha$ /IL-13)<sup>1,2</sup>**  
 NCT04394351 (EOE KIDS)  
 Age 1 to 11 years  
 April 2023

**Dupilumab (IL-4R $\alpha$ /IL-13)<sup>1,2</sup>**  
 NCT03633617 (LIBERTY EoE TREET)  
 Age  $\geq$ 12 years  
 July 2022

**Mepolizumab (IL-5)<sup>1,2</sup>**  
 NCT03656380  
 Age 16 to 75 years  
 July 2022

**Lirentelimab (siglec-8)<sup>1,2</sup>**  
 NCT04322708 (KRYPTOS)  
 Age  $\geq$ 12 and  $\leq$ 80 years  
 May 2022

**Benralizumab (IL-5R $\alpha$ )<sup>1,2</sup>**  
 NCT04543409 (MESSINA)  
 Age  $\geq$ 12 and  $\leq$ 65 years  
 May 2024

**Dupilumab (IL-4R $\alpha$ /IL-13)<sup>1,2</sup>**  
 NCT05247866  
 Age 6 to 25 years  
 September 2025

EoE, eosinophilic oesophagitis; IL, interleukin; IL-4/13R, IL-4/13 receptor; IL-5R, IL-5 receptor; IL-5R $\alpha$ , IL-5 receptor  $\alpha$  subunit; ILC2, type 2 innate lymphoid cells; siglec-8, sialic acid-binding Ig-like lectin 8; SP1R, sphingosine-1-phosphate receptor; TGF- $\beta$ , transforming growth factor- $\beta$ ; Th2, T-helper cell type 2; TNF- $\alpha$ , tumour necrosis factor- $\alpha$ ; TSLP, thymic stromal lymphopoietin.

1. Racca F, et al. *Front Physiol.* 2022;12:815842; 2. ClinicalTrials.gov. Available at: <https://clinicaltrials.gov/ct2/home> (accessed 19 May 2022).